1. Home
  2. SUPV vs ESPR Comparison

SUPV vs ESPR Comparison

Compare SUPV & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Supervielle S.A. each Representing five Class B shares

SUPV

Grupo Supervielle S.A. each Representing five Class B shares

HOLD

Current Price

$10.26

Market Cap

814.9M

Sector

Finance

ML Signal

HOLD

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.19

Market Cap

816.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUPV
ESPR
Founded
1887
2008
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
814.9M
816.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
SUPV
ESPR
Price
$10.26
$3.19
Analyst Decision
Buy
Strong Buy
Analyst Count
4
4
Target Price
$13.00
$8.75
AVG Volume (30 Days)
649.6K
16.8M
Earning Date
05-26-2026
05-07-2026
Dividend Yield
2.19%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
N/A
$403,135,000.00
Revenue This Year
$86.20
N/A
Revenue Next Year
$25.12
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.31
52 Week Low
$4.54
$1.11
52 Week High
$13.55
$4.18

Technical Indicators

Market Signals
Indicator
SUPV
ESPR
Relative Strength Index (RSI) 55.79 67.43
Support Level $9.21 $3.16
Resistance Level $12.27 $3.26
Average True Range (ATR) 0.57 0.02
MACD -0.02 -0.01
Stochastic Oscillator 88.93 78.57

Price Performance

Historical Comparison
SUPV
ESPR

About SUPV Grupo Supervielle S.A. each Representing five Class B shares

Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: